Company intelligence / Profile preview

Ailux Biologics

Somerville, MA, United Statesailux.xtalpi.com ↗

Ownership: Private
Employees: ~100
Development stage: Preclinical

Overview

Ailux Biologics has established a robust AI-powered platform validated through over 30 internal and partner programs. Their lead therapeutic candidate, SIGX1094, is in Phase I trials targeting diffuse gastric cancer and other advanced solid tumors. The company has entered into major licensing agreements with Janssen Biotech and UCB to deploy its AI platforms for accelerated biologic drug discovery.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateProtein
Industry: Biotech

Partnerships

Janssen Biotech / Johnson & Johnson InnovationUCBSignet Therapeutics

Beyond the preview

Go deeper on Ailux Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ailux Biologics.

Explore the full profile